REVIEW OF RESULTS OF DOUBLE BLIND PLACEBO-CONTROLLED STUDY OF PHASE III CLADRIBINE IN TABLETS FOR TREATING MULTIPLE SCLEROSIS - CLARITY

Abstract

There was presented a review of foreign publications of 2009 about the investigation results of clinical effectiveness of Cladribine (in tablets) for treating Multiple Sclerosis.

Keywords

multiple sclerosis / new pharmaceutical forms / investigation of phase III / Cladribine in tablets

References

[1] 1. Comi, G. Reduction in MRI activity in relapsing-remitting multiple sclerosis achieved with cladribine tablets in the 96-week, Phase III, double-blind, placebo-controlled CLARITY study / G. Comi, S. Cook, G. Giovannoni et al. //Multiple Sclerosis. - Vol. 15, suppl.2. - S. 136.

[2] 2. Cook, S. Safety and tolerability of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study / S. Cook, P. Vermersch, G.Comi et al. // Journal of the neurological sciences. - Vol. 285, suppl.1. - S. 206.

[3] 3. Giovannoni, G. Disease activity-free results for cladribine tablets in the 96-week, Phase III, double-blind, placebo-controlled CLARITY study in patients with relapsing-remitting multiple sclerosis / G. Giovannoni, G. Comi, S. Cook et al. // Multiple Sclerosis. - Vol. 15, suppl. 2. - S. 137.

[4] 4. Giovanonni G. Clinical outcomes with cladribine tablets in the 96-week, phase III, double-blind, placebo-controlled CLARITY study in patients with relapsing-remitting multiple sclerosis / G. Giovanonni, G. Comi, S. Cook et.al. // Multiple Sclerosis. - Vol. 15, suppl. 2. - S. 136-137.

[5] 5. Leist, T.P. Mode of action (MoA) of cladribine tablets: activity in lymphocytes and implications for treatment of multiple sclerosis (MS) / T.P. Leist, M. Migliaccio, R. Weissert. // Journal of the neurological sciences. - Vol. 285, suppl.1. - S. 206-207.

[6] 6. Miret, M. Evaluation of the long -term safety of cladribine tablets: design of a prospective 8-year safety registry / M. Miret, L. Perez-Gutthann, V. Viglietta et al. // Multiple Sclerosis. - Vol. 15, suppl. 2. - S. 239.

[7] 7. Soelberg-Sшrensen, P. Effect of cladribine tablets on haematological profiles in patients with relapsing-remitting multiple sclerosis in the 96-week, Phase III, double-blind, placebo-controlled CLARITY study / P. Soelberg-Sшrensen, G. Comi, S. Cook et al. // Multiple Sclerosis. - Vol. 15, suppl. 2. - S. 137.

[8] 8. Vermersch, P. Early onset of effects of treatment with cladribine tablets for relapsing-remitting multiple sclerosis in the 96-week, Phase III, double-blind, placebo-controlled CLARITY study / P. Vermersch, G. Comi, S. Cook et al. // Multiple Sclerosis. - Vol. 15, suppl. 2. - S. 249.

[9] 9. Viglietta, V. Clinical development plan for cladribine tablets, an oral immunomodulator, for the treatment of multiple sclerosis / V. Viglietta, S. Greenberg, D. Mikol et al. // Multiple Sclerosis. Vol. 15, suppl. 2. - S. 126-127.

RIGHTS & PERMISSIONS

Sidorenko T.V.